PKC412
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for PKC412, covering 2015-12-22 to 2017-07-17. Get the full timeline:
Most recent: Clinical Trial Update: PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) [Phase 1, Phase 2]